Literature DB >> 8739974

Treatment of two children with hereditary tyrosinaemia type I and long-standing renal disease with a 4-hydroxyphenylpyruvate dioxygenase inhibitor (NTBC).

E Pronicka1, E Rowinska, Z Bentkowski, J Zawadzki, E Holme, S Lindstedt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8739974     DOI： 10.1007/bf01799438

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN： 0141-8955            Impact factor:   4.982


× No keyword cloud information.
  8 in total

1.  Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment.

Authors:  F J van Spronsen; Y Thomasse; G P Smit; J V Leonard; P T Clayton; V Fidler; R Berger; H S Heymans
Journal:  Hepatology       Date:  1994-11       Impact factor: 17.425

2.  Renal bicarbonate reabsorption and hydrogen ion excretion in normal infants.

Authors:  C M Edelmann; J R Soriano; H Boichis; A B Gruskin; M I Acosta
Journal:  J Clin Invest       Date:  1967-08       Impact factor: 14.808

3.  Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase.

Authors:  S Lindstedt; E Holme; E A Lock; O Hjalmarson; B Strandvik
Journal:  Lancet       Date:  1992-10-03       Impact factor: 79.321

4.  Contribution of extrahepatic tissues to biochemical abnormalities in hereditary tyrosinemia type I: study of three patients after liver transplantation.

Authors:  M Tuchman; D K Freese; H L Sharp; M L Ramnaraine; N Ascher; J R Bloomer
Journal:  J Pediatr       Date:  1987-03       Impact factor: 4.406

5.  Rapid improvement in the renal tubular dysfunction associated with tyrosinemia following hepatic replacement.

Authors:  L R Shoemaker; C F Strife; W F Balistreri; F C Ryckman
Journal:  Pediatrics       Date:  1992-02       Impact factor: 7.124

6.  Renal failure in adult patients with hereditary tyrosinaemia type I.

Authors:  E A Kvittingen; T Talseth; S Halvorsen; C Jakobs; T Hovig; A Flatmark
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

7.  Peripheral neuropathy as the presenting feature of tyrosinaemia type I and effectively treated with an inhibitor of 4-hydroxyphenylpyruvate dioxygenase.

Authors:  T C Gibbs; J Payan; E M Brett; S Lindstedt; E Holme; P T Clayton
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-10       Impact factor: 10.154

8.  The nephropathy of type I tyrosinemia after liver transplantation.

Authors:  J Laine; M K Salo; L Krogerus; J Kärkkäinen; O Wahlroos; C Holmberg
Journal:  Pediatr Res       Date:  1995-05       Impact factor: 3.756
  8 in total
  4 in total

Review 1.  Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione).

Authors:  E Holme; S Lindstedt
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

2.  Therapeutic trials in the murine model of hereditary tyrosinaemia type I: a progress report.

Authors:  M Grompe; K Overturf; M al-Dhalimy; M Finegold
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

Review 3.  New management options for end-stage chronic liver disease and acute liver failure: potential for pediatric patients.

Authors:  Dominique Debray; Nadya Yousef; Philippe Durand
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

4.  Renal tubular function in children with tyrosinaemia type I treated with nitisinone.

Authors:  S Santra; M A Preece; S-A Hulton; P J McKiernan
Journal:  J Inherit Metab Dis       Date:  2008-05-23       Impact factor: 4.750
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.